$LNTH
Lantheus Holdings, Inc. Stock $lnth

$lnth Overview Financials Valuation SEC Filings Company Website

2015 Form 10-K Financial Statement

#000119312516490104 Filed on March 02, 2016

Income Statement

Concept	2015	2014 Q4	2014 Q3
Revenue	$293.5M	$76.97M	$75.68M
YoY Change	-2.7%	7.39%	7.52%
Cost Of Revenue	$157.9M	$44.21M	$44.04M
YoY Change	-10.3%	-28.45%	-5.61%
Gross Profit	$135.5M	$32.76M	$31.64M
YoY Change	7.97%	231.59%	33.38%
Gross Profit Margin	46.18%	42.56%	41.8%
Selling, General & Admin	$78.63M	$16.32M	$19.37M
YoY Change	8.57%	5.7%	24.07%
% of Gross Profit	58.02%	49.82%	61.22%
Research & Development	$14.36M	$4.720M	$3.049M
YoY Change	5.01%	-6.16%	-48.23%
% of Gross Profit	10.59%	14.41%	9.64%
Depreciation & Amortization	$11.80M	$3.440M	$2.200M
YoY Change	19.19%	-0.86%	-70.31%
% of Gross Profit	8.71%	10.5%	6.95%
Operating Expenses	$92.99M	$21.03M	$22.42M
YoY Change	8.0%	81.45%	4.27%
Operating Profit	$42.53M	$11.73M	$9.221M
YoY Change	7.9%	-786.02%	315.36%
Interest Expense	$38.72M	-$10.53M	-$10.50M
YoY Change	-8.45%	-1.22%	-6.33%
% of Operating Profit	91.03%	-89.76%	-113.87%
Other Income/Expense, Net	-$65.00K	$590.0K	$441.0K
YoY Change	-112.87%	34.09%	2.56%
Pretax Income	-$11.78M	$1.800M	-$923.0K
YoY Change	397.8%	-115.57%	-93.98%
Income Tax	$2.968M	$1.570M	-$56.00K
% Of Pretax Income		87.22%
Net Earnings	-$14.70M	$227.0K	-$867.0K
YoY Change	308.33%	-101.85%	-94.24%
Net Earnings / Revenue	-5.01%	0.29%	-1.15%
Basic Earnings Per Share	-$0.60
Diluted Earnings Per Share	-$0.60	$8.706K	-$32.93K
COMMON SHARES
Basic Shares Outstanding	24.44M shares		18.08M shares
Diluted Shares Outstanding	24.44M shares		18.08M shares

Balance Sheet

Concept	2015	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.60M	$19.70M	$27.10M
YoY Change	45.18%	5.91%
Cash & Equivalents	$28.60M	$19.74M	$27.13M
Short-Term Investments
Other Short-Term Assets	$8.500M	$4.374M	$4.200M
YoY Change	93.18%	41.1%
Inventory	$15.60M	$15.58M	$16.40M
Prepaid Expenses
Receivables	$37.30M	$41.54M	$41.20M
Other Receivables	$0.00	$2.000M	$400.0K
Total Short-Term Assets	$90.00M	$81.24M	$89.40M
YoY Change	10.84%	2.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$86.50M	$96.01M	$96.10M
YoY Change	-9.9%	-1.73%
Goodwill		$15.71M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.50M	$20.58M	$27.80M
YoY Change	-0.49%	-36.09%
Total Long-Term Assets	$152.4M	$161.9M	$170.6M
YoY Change	-5.93%	-11.08%
TOTAL ASSETS
Total Short-Term Assets	$90.00M	$81.24M	$89.40M
Total Long-Term Assets	$152.4M	$161.9M	$170.6M
Total Assets	$242.4M	$243.2M	$260.0M
YoY Change	-0.33%	-6.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.70M	$15.67M	$15.40M
YoY Change	-25.48%	-13.45%
Accrued Expenses	$18.50M	$24.90M	$35.10M
YoY Change	-25.7%	-2.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$8.000M	$8.000M
YoY Change	-100.0%	0.0%
Long-Term Debt Due	$3.700M	$0.00
YoY Change
Total Short-Term Liabilities	$35.50M	$48.53M	$59.60M
YoY Change	-26.8%	-12.72%
LONG-TERM LIABILITIES
Long-Term Debt	$349.9M	$392.9M	$399.2M
YoY Change	-10.94%	-1.54%
Other Long-Term Liabilities	$42.30M	$33.60M	$40.00M
YoY Change	3.17%	-20.2%
Total Long-Term Liabilities	$392.2M	$426.5M	$439.2M
YoY Change	-9.61%	-3.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$35.50M	$48.53M	$59.60M
Total Long-Term Liabilities	$392.2M	$426.5M	$439.2M
Total Liabilities	$427.7M	$482.4M	$498.8M
YoY Change	-11.34%	-2.89%
SHAREHOLDERS EQUITY
Retained Earnings		-$344.4M
YoY Change
Common Stock		$106.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)		$106.0K
YoY Change
Treasury Stock Shares		5.037K shares
Shareholders Equity	-$185.3M	-$239.3M	-$238.8M
YoY Change
Total Liabilities & Shareholders Equity	$242.4M	$243.2M	$260.0M
YoY Change	-0.33%	-6.94%

Cashflow Statement

Concept	2015	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$14.70M	$227.0K	-$867.0K
YoY Change	308.33%	-101.85%	-94.24%
Depreciation, Depletion And Amortization	$11.80M	$3.440M	$2.200M
YoY Change	19.19%	-0.86%	-70.31%
Cash From Operating Activities	$21.76M	-$3.880M	$20.52M
YoY Change	87.77%	0.26%	378.32%
INVESTING ACTIVITIES
Capital Expenditures	-$13.15M	-$2.840M	-$1.820M
YoY Change	61.55%	118.46%	100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$230.0K
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$13.15M	-$2.830M	-$1.600M
YoY Change	71.24%	-1330.43%	75.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$73.54M
YoY Change
Debt Paid & Issued, Net	$1.900M
YoY Change	2576.06%
Cash From Financing Activities	$999.0K	-360.0K	-7.330M
YoY Change	-143.43%	80.0%	391.95%
NET CHANGE
Cash From Operating Activities	$21.76M	-3.880M	20.52M
Cash From Investing Activities	-$13.15M	-2.830M	-1.600M
Cash From Financing Activities	$999.0K	-360.0K	-7.330M
Net Change In Cash	$9.610M	-7.070M	11.59M
YoY Change	496.89%	84.11%	513.23%
FREE CASH FLOW
Cash From Operating Activities	$21.76M	-$3.880M	$20.52M
Capital Expenditures	-$13.15M	-$2.840M	-$1.820M
Free Cash Flow	$34.91M	-$1.040M	$22.34M
YoY Change	76.95%	-59.53%	329.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31478119	shares
CY2015Q2	dei	Entity Public Float EntityPublicFloat	0
CY2012Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	5416000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-173105000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14781000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	125782000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33321000
CY2013Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	6385000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-235517000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14002000
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	151339000
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	162618000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18578000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1531110	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.57
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18075907	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18080944	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	106699000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	704000
CY2014Q4	us-gaap	Deferred Tax Liabilities Gross Current DeferredTaxLiabilitiesGrossCurrent	152000
CY2014Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	7435000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11198000
CY2014Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	978000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-239270000
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	392863000
CY2014Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	24863000
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33597000
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1508000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	134502000
CY2014Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	33200000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12144000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15665000
CY2014Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	642000
CY2014Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	8000000
CY2014Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	12400000
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	600000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-344414000
CY2014Q4	us-gaap	Liabilities Liabilities	482423000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	243153000
CY2014Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	18600000
CY2014Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	400000000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	181000
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	400000
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6749000
CY2014Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	2200000
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61432000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48528000
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	152138000
CY2014Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	6012000
CY2014Q4	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	247000
CY2014Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	95000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1630000
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4994000
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1788000
CY2014Q4	us-gaap	Deferred Tax Assets Gross Noncurrent DeferredTaxAssetsGrossNoncurrent	328000
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	46843000
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	159072000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20578000
CY2014Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	2421000
CY2014Q4	us-gaap	Assets Assets	243153000
CY2014Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1156000
CY2014Q4	us-gaap	Inventory Net InventoryNet	15582000
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41540000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96014000
CY2014Q4	us-gaap	Noncurrent Assets NoncurrentAssets	96014000
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7751000
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	106000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	81235000
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4374000
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	185000
CY2014Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	10950000
CY2014Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2000000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	161693000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	38285000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27191000
CY2014Q4	us-gaap	Goodwill Goodwill	15714000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19739000
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6043000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3979000
CY2014Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	256000
CY2014Q4	us-gaap	Other Inventory Capitalized Costs OtherInventoryCapitalizedCosts	0
CY2014Q4	lnth	Inventory Raw Materials Noncurrent InventoryRawMaterialsNoncurrent	1200000
CY2015	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	360438000
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	1359000
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43894000
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2431000
CY2015	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	187000
CY2015	us-gaap	Advertising Expense AdvertisingExpense	3100000
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	265000
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2869000
CY2014Q4	lnth	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	26471000
CY2014Q4	lnth	Tax Indemnification Receivable TaxIndemnificationReceivable	17800000
CY2014Q4	lnth	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	36523000
CY2014Q4	lnth	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	16738000
CY2014Q4	lnth	Accrued Freight Costs Current AccruedFreightCostsCurrent	3069000
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1493000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	136561000
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33947000
CY2014Q4	lnth	Accrued Rebates And Allowances Current AccruedRebatesAndAllowancesCurrent	2200000
CY2014Q4	lnth	Accrued Rebates Discounts And Chargebacks Current AccruedRebatesDiscountsAndChargebacksCurrent	2164000
CY2014Q4	lnth	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	248000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1180973	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.95
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30364501	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.87
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	877218	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30364501	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.05
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1150453	shares
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	387000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	481000
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	175553000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	687000
CY2015Q4	us-gaap	Deferred Tax Liabilities Gross Current DeferredTaxLiabilitiesGrossCurrent	194000
CY2015Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	8145000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2787000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10525000
CY2015Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	490000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-185289000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	295000
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	349858000
CY2015Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	18696000
CY2015Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	33800000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11450000
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3650000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11657000
CY2015Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	399000
CY2015Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	11700000
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	900000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359160000
CY2015Q4	us-gaap	Liabilities Liabilities	427668000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	242379000
CY2015Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	19900000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	303000
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	400000
CY2015Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	0
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4957000
CY2015Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	2200000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	370000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	67260000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	883000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35718000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	154252000
CY2015Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	4558000
CY2015Q4	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	53000
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1985000
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	94000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	371000
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2407000
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2015Q4	us-gaap	Deferred Tax Assets Gross Noncurrent DeferredTaxAssetsGrossNoncurrent	320000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	72416000
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2301000
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5600000
CY2015Q4	us-gaap	Trade And Loans Receivables Held For Sale Net Not Part Of Disposal Group TradeAndLoansReceivablesHeldForSaleNetNotPartOfDisposalGroup	2512000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	159377000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20414000
CY2015Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	9137000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2015Q4	us-gaap	Assets Assets	242379000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2683000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3386000
CY2015Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	4644000
CY2015Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1156000
CY2015Q4	us-gaap	Inventory Net InventoryNet	15622000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37293000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	86517000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5165000
CY2015Q4	us-gaap	Noncurrent Assets NoncurrentAssets	86517000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	5838000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	90101000
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3946000
CY2015Q4	lnth	Liabilities Held For Sale Not Part Of Disposal Group LiabilitiesHeldForSaleNotPartOfDisposalGroup	1715000
CY2015Q4	lnth	Intangibles Held For Sale Not Part Of Disposal Group Non Current IntangiblesHeldForSaleNotPartOfDisposalGroupNonCurrent	480000
CY2015Q4	lnth	Other Long Term Asset Held For Sale Not Part Of Disposal Group Non Current OtherLongTermAssetHeldForSaleNotPartOfDisposalGroupNonCurrent	29000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1592000
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5709000
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	168000
CY2015Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	11112000
CY2015Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1000000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	157057000
CY2015Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current Other AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther	26000
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	30564000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20496000
CY2015Q4	us-gaap	Goodwill Goodwill	15714000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28596000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1832000
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7506000
CY2015Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	4644000
CY2015Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	95000
CY2015Q4	us-gaap	Other Inventory Capitalized Costs OtherInventoryCapitalizedCosts	0
CY2015Q4	lnth	Inventory Raw Materials Noncurrent InventoryRawMaterialsNoncurrent	1200000
CY2015Q4	lnth	Unrecognized Tax Benefits For Transfer Pricing Exposure Included In Other Long Term Liabilities UnrecognizedTaxBenefitsForTransferPricingExposureIncludedInOtherLongTermLiabilities	600000
CY2015Q4	lnth	Asset Retirement Obligation Liabilities Expected Present Value AssetRetirementObligationLiabilitiesExpectedPresentValue	26600000
CY2015Q4	lnth	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	22431000
CY2015Q4	lnth	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	20553000
CY2015Q4	lnth	Number Of Radiopharmacies Owned NumberOfRadiopharmaciesOwned	3	Item
CY2015Q4	lnth	Finite Lived Intangible Assets Held For Sale FiniteLivedIntangibleAssetsHeldForSale	3188000
CY2015Q4	lnth	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	16778000
CY2015Q4	lnth	Unrecognized Tax Benefits For Transfer Pricing Exposure Included In Other Long Term Assets UnrecognizedTaxBenefitsForTransferPricingExposureIncludedInOtherLongTermAssets	200000
CY2015Q4	lnth	Number Of Commercial Products NumberOfCommercialProducts	10	Item
CY2015Q4	lnth	Accrued Freight Costs Current AccruedFreightCostsCurrent	2962000
CY2015Q4	lnth	Consolidated Fixed Charge Coverage Ratio ConsolidatedFixedChargeCoverageRatio	1	pure
CY2015Q4	lnth	Tax Indemnification Receivable TaxIndemnificationReceivable	17600000
CY2015Q4	lnth	Accrued Rebates And Allowances Current AccruedRebatesAndAllowancesCurrent	2300000
CY2015Q4	lnth	Accrued Rebates Discounts And Chargebacks Current AccruedRebatesDiscountsAndChargebacksCurrent	2085000
CY2015Q4	lnth	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	360000
CY2015Q4	lnth	Inventory Held For Sale Not Part Of Disposal Group Current InventoryHeldForSaleNotPartOfDisposalGroupCurrent	806000
CY2015Q4	lnth	Property Plant And Equipment Held For Sale Not Part Of Disposal Group Non Current PropertyPlantAndEquipmentHeldForSaleNotPartOfDisposalGroupNonCurrent	791000
CY2015Q4	lnth	Accrued Expense And Other Liabilities Held For Sale Not Part Of Disposal Group AccruedExpenseAndOtherLiabilitiesHeldForSaleNotPartOfDisposalGroup	1285000
CY2015Q4	lnth	Accounts Payable Held For Sale Not Part Of Disposal Group AccountsPayableHeldForSaleNotPartOfDisposalGroup	430000
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-61555000
CY2015Q2	lnth	Accrued Interest Paid AccruedInterestPaid	3300000
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	10900000
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15572000
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.42
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.45
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18032131000	shares
CY2013	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	369000
CY2013	us-gaap	Revenues Revenues	283672000
CY2013	us-gaap	Interest Paid InterestPaid	39150000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	578000
CY2013	us-gaap	Payments Of Dividends PaymentsOfDividends	123000
CY2013	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	566000
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	400000
CY2013	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	106000
CY2013	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	8876000
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-18891000
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4741000
CY2013	us-gaap	Gross Profit GrossProfit	77361000
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1161000
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	25557000
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2627000
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1729000
CY2013	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1026000
CY2013	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-349000
CY2013	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2013	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1310000
CY2013	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5010000
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63284000
CY2013	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1249000
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-60541000
CY2013	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	341000
CY2013	us-gaap	Capitalized Computer Software Amortization CapitalizedComputerSoftwareAmortization	1500000
CY2013	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1729000
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	104000
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1346000
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	118000
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-57970000
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2571000
CY2013	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1243000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	18000
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	237000
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-60541000
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1014000
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	578000
CY2013	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	187000
CY2013	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	809000
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2013	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	31000
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	34000
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	356000
CY2013	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	35227000
CY2013	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	0
CY2013	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	628000
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	292000
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-51000
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000
CY2013	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	106000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14743000
CY2013	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-272000
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	25631000
CY2013	us-gaap	Operating Expenses OperatingExpenses	96252000
CY2013	us-gaap	Interest Expense InterestExpense	42915000
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3483000
CY2013	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	-18000
CY2013	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	6406000
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5612000
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30459000
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-272000
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	400000
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1527000
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1200000
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-1300000
CY2013	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	1900000
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9633000
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1712000
CY2013	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	92000
CY2013	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-1465000
CY2013	us-gaap	Inventory Write Down InventoryWriteDown	4854000
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33036000
CY2013	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	8000000
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2600000
CY2013	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	410000
CY2013	us-gaap	Advertising Expense AdvertisingExpense	2700000
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-782000
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-21181000
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14400000
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1286000
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	206311000
CY2013	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	20500000
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1147000
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25783000
CY2013	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	598000
CY2013	us-gaap	Depreciation Depreciation	9300000
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	763000
CY2013	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	17175000
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	63000
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1780000
CY2013	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	1141000
CY2013	lnth	Rebates And Allowances Charges RebatesAndAllowancesCharges	4800000
CY2013	lnth	Amortization Of Deferred Financing Costs AmortizationOfDeferredFinancingCosts	2400000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	11590000
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.70
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18080615000	shares
CY2014	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3000
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3561000
CY2014	us-gaap	Revenues Revenues	301600000
CY2014	us-gaap	Interest Paid InterestPaid	39214000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1031000
CY2014	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-2719000
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2064000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	39417000
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1500000
CY2014	us-gaap	Gross Profit GrossProfit	125519000
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	478000
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	958000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3563000
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1236000
CY2014	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	865000
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-279000
CY2014	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2014	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	71000
CY2014	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	8137000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4797000
CY2014	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	175000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2366000
CY2014	us-gaap	Capitalized Computer Software Amortization CapitalizedComputerSoftwareAmortization	700000
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1236000
CY2014	us-gaap	Asset Retirement Obligation Liabilities Incurred AssetRetirementObligationLiabilitiesIncurred	277000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4047000
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19024000
CY2014	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	2392000
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	27000
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1204000
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	508000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	2201000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4567000
CY2014	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2916000
CY2014	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	5500000
CY2014	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	215000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2366000
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1195000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1031000
CY2014	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-2560000
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	8000
CY2014	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	817000
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-277000
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2014	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	61000
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	1434000
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	325000
CY2014	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	35116000
CY2014	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	0
CY2014	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	773000
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	149000
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	6000
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1000000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1161000
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	70000
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	958000
CY2014	us-gaap	Operating Expenses OperatingExpenses	86102000
CY2014	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	1700000
CY2014	us-gaap	Interest Expense InterestExpense	42288000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-7682000
CY2014	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	-500000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2297000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13673000
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-207000
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13000
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	227000
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1500000
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-450000
CY2014	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	1200000
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4937000
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1285000
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2708000
CY2014	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	754000
CY2014	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	437000
CY2014	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	1065000
CY2014	us-gaap	Inventory Write Down InventoryWriteDown	1593000
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37313000
CY2014	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	68000
CY2014	us-gaap	Advertising Expense AdvertisingExpense	2800000
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-208000
CY2014	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	5500000
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7600000
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	176081000
CY2014	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	19400000
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1402000
CY2014	us-gaap	Finite Lived Intangible Assets Translation Adjustments FiniteLivedIntangibleAssetsTranslationAdjustments	-925000
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-828000
CY2014	lnth	Rebates And Allowances Charges RebatesAndAllowancesCharges	5200000
CY2014	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	228000
CY2014	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	132000
CY2014	us-gaap	Depreciation Depreciation	9900000
CY2014	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	416000
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	303000
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	234000
CY2014	lnth	Deferred Tax Assets Valuation Allowance Foreign Currency Translation Adjustments DeferredTaxAssetsValuationAllowanceForeignCurrencyTranslationAdjustments	159000
CY2014	lnth	Amortization Of Deferred Financing Costs AmortizationOfDeferredFinancingCosts	2500000
CY2014	lnth	Number Of Customers Representing Greater Than Ten Percent Of Accounts Receivable NumberOfCustomersRepresentingGreaterThanTenPercentOfAccountsReceivable	3	Customer
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>1. Description of Business</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Overview</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Holdings, a Delaware corporation, is the parent company of LMI, also a Delaware corporation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company develops, manufactures and commercializes innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. The Company sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations and, in certain circumstances, wholesalers. The Company sells its products globally and has operations in the United States, Canada, Puerto Rico and Australia and distribution relationships in Europe, Asia Pacific and Latin America.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company’s portfolio of 10 commercial products is diversified across a range of imaging modalities. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the United States, is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">TechneLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Xenon Xe 133 Gas, or Xenon, is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name sestamibi, used with Single Photon Emission Computed Tomography, or SPECT, technology in myocardial perfusion imaging, or MPI, procedures that assess blood flow distribution to the heart.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Neurolite is an injectable, technetium-labeled imaging agent used with SPECT technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In the United States, the Company sells DEFINITY through its sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company’s radiopharmaceutical products are primarily distributed through commercial radiopharmacies owned or controlled by third parties. In Puerto Rico and Australia, the Company owns three radiopharmacies and sells its own radiopharmaceuticals, as well as others, directly to end users. In Canada, Europe, Asia Pacific and Latin America, the Company utilizes distributor relationships to market, sell and distribute its products.</p> </div>
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	21762000
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	Segment
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.60
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001521036
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2015	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>Concentration of Risks and Limited Suppliers</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to large national distributors, which in turn, may resell the Company’s products. There were three customers that represented greater than 10% of the total net accounts receivable balance at either December 31, 2015 or 2014. The same three customers contributed revenues of 12%, 11% and 10% during the year ended December 31, 2015, which is included in the U.S. segment. No other customers contributed more than 10% of revenue in any of the years ended December 31, 2015, 2014 and 2013.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Accounts<br /> Receivable as<br /> of December 31,</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Revenue for the year<br /> ended December 31,</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>  2015  </b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>  2014  </b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>  2015  </b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>  2014  </b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>  2013  </b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Company A</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.8</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16.5</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.3</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.8</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Company B</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12.9</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.4</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.9</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.1</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.2</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Company C</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.3</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.8</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.8</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.8</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company’s cash and cash equivalents are maintained with various financial institutions.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and thereby adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations. The Company has agreements with Nordion and NTP/ANSTO, the Company’s Moly suppliers, with an expiration dates of October 31, 2016 and December 31, 2017, respectively. In addition, because Xenon is a by-product of the Moly production process and is currently captured only by Nordion, the Company is currently reliant on Nordion as the sole supplier of Xenon to meet customer demand. In March 2013, the Company entered into an agreement with Institute for Radioelements, or IRE, who had previously been supplying the Company with Moly under the previous agreement with NTP, and this agreement expires on December 31, 2017. In January 2015, the Company announced entering into a new strategic agreement with IRE for the future supply of Xenon. Under the terms of the agreement, IRE will provide bulk Xenon to us for processing and finishing once development work has been completed and all necessary regulatory approvals have been obtained.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company currently relies on JHS as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials. The Company has additional ongoing technology transfer activities at JHS for its Cardiolite product supply. In the meantime, the Company has no other currently active supplier of DEFINITY, Neurolite, and its Cardiolite product supply is approved for manufacture by a single manufacturer.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Based on current projections, the Company believes that it will have sufficient supply of DEFINITY, Neurolite and evacuation vials from JHS to meet expected demand and sufficient Cardiolite product supply and saline from the Company’s current suppliers to meet expected demand.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is working to secure additional alternative suppliers for its key products as part of its ongoing supply chain diversification strategy. On November 12, 2013, the Company entered into a Manufacturing and Supply Agreement with Pharmalucence to manufacture and supply DEFINITY. However, the Company is uncertain on the timing in which the Pharmalucence arrangement or any other arrangements could provide meaningful quantities of product.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The following table sets forth revenues for the Company’s products that represented greater than 10% of total revenue for the years ended December 31, 2015, 2014 and 2013.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended<br /> December 31,</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> DEFINITY</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38.1</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31.8</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27.5</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> TechneLite</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32.5</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Xenon</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12.1</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.3</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>
CY2015	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	132000
CY2015	us-gaap	Common Stock Voting Rights CommonStockVotingRights	One vote per share
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2015	dei	Entity Registrant Name EntityRegistrantName	LANTHEUS HOLDINGS, INC.
CY2015	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Distributor Relationships</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Revenue for product sold to distributors is recognized at shipment, unless revenue recognition criteria have not been met. In those instances where collectability cannot be determined or the selling price cannot be reasonably estimated until the distributor has sold through the goods, the Company defers that revenue until such time as the goods have been sold through to the end-user customer, or the selling price can be reasonably estimated based on history of transactions with that distributor.</p> </div>
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.11
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.355872	pure
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2704000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	281474	shares
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	592179	shares
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2015	us-gaap	Revenue Recognition Sales Returns RevenueRecognitionSalesReturns	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Product Returns</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company provides a reserve for its estimate of sales recorded for which the related products are expected to be returned. The Company does not typically accept product returns unless an over shipment or non-conforming shipment was provided to the customer, or if the product was defective. The Company adjusts its estimate of product returns if it becomes aware of other factors that it believes could significantly impact its expected returns, including product recalls. These factors include its estimate of actual and historical return rates for non-conforming product and open return requests. Historically, the Company’s estimates of returns have reasonably approximated actual returns.</p> </div>
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.44
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	400000000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14000
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-355000
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	120000
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	174000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2670000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-9108000
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1752000
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1900000
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1125000
CY2015	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	9752000
CY2015	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	8000000
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1894000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11778000
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</p> </div>
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2015	dei	Trading Symbol TradingSymbol	LNTH
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24439845000	shares
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	200000
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-15528000
CY2015	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	13151000
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-5000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8857000
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	99000
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2704000
CY2015	us-gaap	Operating Expenses OperatingExpenses	92992000
CY2015	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	7900000
CY2015	us-gaap	Interest Expense InterestExpense	38715000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-13151000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	999000
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14358000
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	24000
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M6D
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	17.71
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y4M24D
CY2015	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	6362000
CY2015	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	8000
CY2015	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	97000
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14746000
CY2015	us-gaap	Revenues Revenues	293461000
CY2015	us-gaap	Interest Paid InterestPaid	40788000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2002000
CY2015	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-230000
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	563000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	42530000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2609000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	99000
CY2015	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	97000
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1600000
CY2015	us-gaap	Gross Profit GrossProfit	135522000
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-89000
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-753000
CY2015	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	2500000
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3986000
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2386000
CY2015	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	46000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15101000
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	6304000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11778000
CY2015	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	1191000
CY2015	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	-37000
CY2015	us-gaap	Capitalized Computer Software Amortization CapitalizedComputerSoftwareAmortization	1100000
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-355000
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	218000
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	34740000
CY2015	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	0
CY2015	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	747000
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-476000
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2968000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	2002000
CY2015	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	638000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	6362000
CY2015	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	2523000
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2015	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	749000
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	694000
CY2015	us-gaap	Finite Lived Intangible Assets Translation Adjustments FiniteLivedIntangibleAssetsTranslationAdjustments	-1448000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4122000
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6000000
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	157939000
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	73539000
CY2015	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	17400000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1680000
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19651000
CY2015	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	236000
CY2015	us-gaap	Depreciation Depreciation	11800000
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	773000
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	478000
CY2015	lnth	Financial Assurance In Form Of Surety Bond FinancialAssuranceInFormOfSuretyBond	28200000
CY2015	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	1655000
CY2015	lnth	Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice	19.78
CY2015	lnth	Rebates And Allowances Charges RebatesAndAllowancesCharges	5900000
CY2015	lnth	Income Tax Returns Period Subject To Examination IncomeTaxReturnsPeriodSubjectToExamination	P3Y
CY2015	lnth	Deferred Tax Assets Valuation Allowance Foreign Currency Translation Adjustments DeferredTaxAssetsValuationAllowanceForeignCurrencyTranslationAdjustments	590000
CY2015	lnth	Amortization Of Deferred Financing Costs AmortizationOfDeferredFinancingCosts	1900000
CY2015	lnth	Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod	39432	shares
CY2015	lnth	Number Of Methods Utilized To Derive Fair Value Of Business NumberOfMethodsUtilizedToDeriveFairValueOfBusiness	2	Method
CY2015	lnth	Period For Which Domestic Pre Tax Losses Were Generated PeriodForWhichDomesticPreTaxLossesWereGenerated	P2Y
CY2015	lnth	Financial Assurance In Form Of Letter Of Credit FinancialAssuranceInFormOfLetterOfCredit	8800000
CY2015	lnth	Period Over Which Cumulative Loss Was Incurred PeriodOverWhichCumulativeLossWasIncurred	P3Y
CY2015	lnth	Number Of Customers Representing Greater Than Ten Percent Of Accounts Receivable NumberOfCustomersRepresentingGreaterThanTenPercentOfAccountsReceivable	3	Customer
CY2015	lnth	Percentage Of Greatest Amount Of Letter Of Credit Drawn PercentageOfGreatestAmountOfLetterOfCreditDrawn	1.05	pure
CY2015	lnth	Purchase Price From Sale Of Assets PurchasePriceFromSaleOfAssets	9000000
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-1285000
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	73336000
CY2014Q1	us-gaap	Gross Profit GrossProfit	30061000
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.02
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	375000
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	74823000
CY2015Q1	us-gaap	Gross Profit GrossProfit	35769000
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1636000
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	75613000
CY2014Q2	us-gaap	Gross Profit GrossProfit	31059000
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.29
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-24423000
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	73314000
CY2015Q2	us-gaap	Gross Profit GrossProfit	32667000
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-867000
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	75682000
CY2014Q3	us-gaap	Gross Profit GrossProfit	31638000
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.18
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	5386000
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	74123000
CY2015Q3	us-gaap	Gross Profit GrossProfit	33705000
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.01
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	227000
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	76969000
CY2014Q4	us-gaap	Gross Profit GrossProfit	32761000
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.13
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	3916000
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	71201000
CY2015Q4	us-gaap	Gross Profit GrossProfit	33381000

Files In Submission

Name	View Source	Status
0001193125-16-490104-index-headers.html	Edgar Link	pending
0001193125-16-490104-index.html	Edgar Link	pending
0001193125-16-490104.txt	Edgar Link	pending
0001193125-16-490104-xbrl.zip	Edgar Link	pending
d117052d10k.htm	Edgar Link	pending
d117052dex1053.htm	Edgar Link	pending
d117052dex211.htm	Edgar Link	pending
d117052dex231.htm	Edgar Link	pending
d117052dex311.htm	Edgar Link	pending
d117052dex312.htm	Edgar Link	pending
d117052dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g117052g90w21.jpg	Edgar Link	pending
g117052g97f59.jpg	Edgar Link	pending
lnth-20151231.xml	Edgar Link	completed
lnth-20151231.xsd	Edgar Link	pending
lnth-20151231_cal.xml	Edgar Link	unprocessable
lnth-20151231_def.xml	Edgar Link	unprocessable
lnth-20151231_lab.xml	Edgar Link	unprocessable
lnth-20151231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LNTH
Lantheus Holdings, Inc. Stock $lnth

2015 Form 10-K Financial Statement

#000119312516490104 Filed on March 02, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNTH Lantheus Holdings, Inc. Stock $lnth

2015 Form 10-K Financial Statement

#000119312516490104 Filed on March 02, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNTH
Lantheus Holdings, Inc. Stock $lnth